Biotechnology / Psychedelic-Assisted Mental Health Therapeutics
Strategic Profile
COMP360 has Breakthrough Therapy designation from the FDA and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression. Recent capital raises of $150 million and $200 million from warrant exercises will fund Phase 3 COMP360 trials, PTSD studies, and commercial preparation efforts, with cash runway extended into 2028.
Cyborg Score Rationale
The company achieved a major clinical milestone with its Phase 3 trial meeting primary endpoints with high significance, positioning COMP360 as a potential first-in-class therapy for treatment-resistant depression with FDA filing underway. Recent financing activities ($200M warrant exercise + $141M public offering) extend the company's cash runway into 2028, supporting development momentum. However, weak financial performance including no revenue and escalating losses present execution risks.
Top Insights
Phase 3 trial met primary endpoint with 32% stock surge driven by breakthrough depression treatment efficacy and safety results (February 2026)
FDA accepted IND application for COMP360 in PTSD in January 2026, enabling late-stage clinical trial initiation alongside commercial readiness for TRD launch by year-end
Secured $341M in total capital ($150M public offering + $200M warrant exercise) to fund Phase 3 COMP005/COMP006 trials and PTSD Phase 2b/3 trial through 2028
Analyst consensus updated with Buy rating at $18 price target, reflecting confidence in regulatory and commercial trajectory
Named Competitors
Psilocybin-Assisted Therapy — Multiple psychedelic therapeutic development programs
Ketamine Infusions — Esketamine (Spravato) for treatment-resistant depression
Traditional Antidepressants — SSRI and other conventional depression treatments
Recent Developments
(February 2026) Warrant exercise of $200M completed; cash runway extended to 2028
(February 2026) COMP360 Phase 3 trial for TRD achieved primary endpoint; $150M public offering completed
(January 2026) FDA accepted COMP360 IND application for PTSD late-stage trial initiation